Biovica International AB (publ) (9II.F)
- Previous Close
0.1550 - Open
0.1550 - Bid --
- Ask --
- Day's Range
0.1550 - 0.1550 - 52 Week Range
0.1012 - 0.8420 - Volume
50 - Avg. Volume
0 - Market Cap (intraday)
15.584M - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2200 - Earnings Date Jun 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a biomarker assay that measures thymidine kinase activity, which reflects tumor cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
www.biovica.comRecent News: 9II.F
Performance Overview: 9II.F
Trailing total returns as of 5/30/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9II.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9II.F
Valuation Measures
Market Cap
15.49M
Enterprise Value
7.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.88
Price/Book (mrq)
1.10
Enterprise Value/Revenue
12.93
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.37%
Return on Equity (ttm)
-78.73%
Revenue (ttm)
6.96M
Net Income Avi to Common (ttm)
-122.99M
Diluted EPS (ttm)
-0.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
105.24M
Total Debt/Equity (mrq)
6.04%
Levered Free Cash Flow (ttm)
-72.85M
Company Insights: 9II.F
9II.F does not have Company Insights